A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

This Phase 1 study tests TGI-5, a new cancer drug, alone and combined with nivolumab (an immunotherapy), to assess safety and early effectiveness in adults with advanced or metastatic solid tumors — including colorectal cancer, melanoma, and non-small cell lung cancer — that have not responded to standard treatments. **You may be eligible if...** - You are 18 or older with advanced solid tumors that have progressed on all standard therapies - You have colorectal cancer, melanoma, non-small cell lung cancer, or another advanced solid tumor - You have at least one measurable lesion on imaging - Your overall health status is good (ECOG 0–2) - Your liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread to the brain (with some exceptions for previously treated, stable brain metastases) - You have active hepatitis B, hepatitis C, HIV, or tuberculosis - You have active autoimmune disease requiring systemic treatment - You have severe heart problems or had a heart attack in the past 6 months - You are pregnant or breastfeeding - You have previously received a TIGIT-targeting therapy Talk to your doctor to see if this trial is right for you.